Drugs

, Volume 72, Issue 8, pp 1011–1028

Management of Metastatic Castration-Resistant Prostate Cancer

Recent Advances
  • Deborah Mukherji
  • Andrew Eichholz
  • Johann S. De Bono
Leading Article

Abstract

Metastatic prostate cancer remains a considerable therapeutic challenge; however, advances in clinical research have resulted in five new treatments in the last 2 years. The immunotherapy sipuleucel-T, the cytotoxic cabazitaxel, the androgen biosynthesis inhibitor abiraterone acetate, the radioisotope al-pharadin and the anti-androgen MDV3100 have all been shown to improve overall survival in randomized phase III studies for patients with metastatic castration-resistant prostate cancer. The therapeutic strategies of targeting androgen-receptor signalling and other key intracellular pathways involved in tumour progression and treatment resistance are yielding promising results. Agents such as the dual vascular endothelial growth factor receptor/MET inhibitor cabozantinib, the clusterin inhibitor custirsen and the Src inhibitor dasatinib have shown encouraging results in phase II studies. Novel immunotherapeutics such as prostate-specific membrane antigen-directed therapy and the anti-cytotoxic T lymphocyte-associated receptor 4 (CTLA4) antibody ipilimumab are also under investigation. Optimal methods of treatment selection, combination and sequencing have yet to be determined.

References

  1. 1.
    Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010 Sep 1; 60 (5): 277–300PubMedCrossRefGoogle Scholar
  2. 2.
    La Vecchia C, Bosetti C, Lucchini F, et al. Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Ann Oncol 2010 Jun; 21 (6): 1323–60PubMedCrossRefGoogle Scholar
  3. 3.
    Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010 Jul 29; 363 (5): 411–22PubMedCrossRefGoogle Scholar
  4. 4.
    de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010 Oct 2; 376 (9747): 1147–54PubMedCrossRefGoogle Scholar
  5. 5.
    de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011 May 26; 364 (21): 1995–2005PubMedCrossRefGoogle Scholar
  6. 6.
    Parker C, Heinrich D, O’Sullivan JM, et al. Overall survival benefit of radium-223 chloride (Alpharadin™) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA). European Multi-disciplinary Cancer Congress; 2011 Sep 23–27; StockholmGoogle Scholar
  7. 7.
    Scher HI FK, Saad F, Taplin ME, et al., for the AFFIRM Investigators. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study. J Clin Oncol 2012; 30 Suppl. 5: LBA 1Google Scholar
  8. 8.
    Fleming MT, Morris MJ, Heller G, et al. Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat Clin Pract Oncol 2006 Dec; 3 (12): 658–67PubMedCrossRefGoogle Scholar
  9. 9.
    de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008 Oct 1; 14 (19): 6302–9PubMedCrossRefGoogle Scholar
  10. 10.
    Scher HI, Jia X, de Bono JS, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009 Mar; 10 (3): 233–9PubMedCrossRefGoogle Scholar
  11. 11.
    Olmos D, Arkenau HT, Ang JE, et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol 2009 Jan; 20 (1): 27–33PubMedCrossRefGoogle Scholar
  12. 12.
    Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999 Nov; 17 (11): 3461–7PubMedGoogle Scholar
  13. 13.
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 Feb 2; 92 (3): 205–16Google Scholar
  14. 14.
    Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008 Mar 1; 26 (7): 1148–59PubMedCrossRefGoogle Scholar
  15. 15.
    Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009 Jan; 45 (2): 228–47PubMedCrossRefGoogle Scholar
  16. 16.
    Ryan CJ, Shah S, Efstathiou E, et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 2011 Jul 15; 17 (14): 4854–61PubMedCrossRefGoogle Scholar
  17. 17.
    Messiou C, Collins DJ, Giles S, et al. Assessing response in bone metastases in prostate cancer with diffusion weighted MRI. Eur Radiol 2011 Oct; 21 (10): 2169–77PubMedCrossRefGoogle Scholar
  18. 18.
    Picchio M, Spinapolice EG, Fallanca F, et al. [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging 2012 Jan; 39 (1): 13–26PubMedCrossRefGoogle Scholar
  19. 19.
    Brown JE, Sim S. Evolving role of bone biomarkers in castration-resistant prostate cancer. Neoplasia 2010 Sep; 12 (9): 685–96PubMedGoogle Scholar
  20. 20.
    Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007 Sep 1; 25 (25): 3965–70PubMedCrossRefGoogle Scholar
  21. 21.
    Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006 Jul 15; 12 (14 Pt 1): 4218–24Google Scholar
  22. 22.
    Tol J, Koopman M, Miller MC, et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol 2010 May; 21 (5): 1006–12PubMedCrossRefGoogle Scholar
  23. 23.
    Scher HI, Heller G, Molina AS, et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel [abstract LBA4517]. J Clin Oncol 2011; 29 Suppl.Google Scholar
  24. 24.
    Danila DC, Fleisher M, Scher HI. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 2011 Jun 15; 17 (12): 3903–2PubMedCrossRefGoogle Scholar
  25. 25.
    Attard G, Swennenhuis JF, Olmos D, et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009 Apr 1; 69 (7): 2912–8PubMedCrossRefGoogle Scholar
  26. 26.
    Darshan MS, Loftus MS, Thadani-Mulero M, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 2011 Sep 15; 71 (18): 6019–29PubMedCrossRefGoogle Scholar
  27. 27.
    Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004 Mar 15; 22 (6): 1025–33PubMedCrossRefGoogle Scholar
  28. 28.
    O’Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004 Jun 14; 90 (12): 2317–25PubMedGoogle Scholar
  29. 29.
    Attard G, Reid AH, A’Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009 Aug 10; 27 (23): 3742–8PubMedCrossRefGoogle Scholar
  30. 30.
    Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010 Mar 20; 28 (9): 1481–8PubMedCrossRefGoogle Scholar
  31. 31.
    Cougar Biotechnology, Inc. Abirateron acetate in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer [ClinicalTrials.gov identifier NCT00887198]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 4]
  32. 32.
    Johnson & Johnson. Study unblinded: ZYTIGA® (abiraterone acetate) plus prednisone for asymptomatic or mildly symptomatic chemotherapy-naive patients with metastatic castration-resistant prostate cancer [media release]. 2012 [online]. Available from URL: http://www.jnj.com/connect/news/all/study-unblinded-zytiga-abiraterone-acetate-plus-prednisone-for-asymptomatic-or-mildly-symptomatic-chemotherapy-naive-patients-with-metastatic-castration-resistant-prostate-cancer [Accessed 2012 Mar 17]
  33. 33.
    Cougar Biotechnology, Inc. Neo-adjuvant abiraterone+luteinizing hormone-releasing hormone (LHRH) versus LHRH in prostate cancer [ClinicalTrials.gov identifier NCT01088529]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 4]
  34. 34.
    Cougar Biotechnology, Inc. Neoadjuvant abiraterone acetate plus leuprolide acetate in men with localized high risk prostate cancer [ClinicalTrials.gov identifier NCT00924469]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 4]
  35. 35.
    Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium. Abiraterone acetate, prednisone and leuprolide acetate or goserelin before and during radiation therapy in treating patients with localized or locally advanced prostate cancer [ClinicalTrials. gov identifier NCT01023061]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 4]
  36. 36.
    Agus DB SM, Shevrin DH, Hart L, et al. Safety, efficacy, and pharmacodynamics of the investigational agent or-teronel (TAK-700) in metastatic castration-resistant prostate cancer (mCRPC): updated data from a phase I/II study [abstract no. 98]. J Clin Oncol 2012; 30 Suppl. 5Google Scholar
  37. 37.
    Millennium Pharmaceuticals, Inc. Study comparing orteronel plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer [Clinical-Trials.gov identifier NCT01193244]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 4]
  38. 38.
    Millennium Pharmaceuticals, Inc. Study comparing orteronel plus prednisone in patients with metastatic castration-resistant prostate cancer [ClinicalTrials.gov identifier NCT01193257]. US National Institutes of Health, Clinical-Trials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 4]
  39. 39.
    Millennium Pharmaceuticals, Inc. Safety and efficacy study of TAK-700 in patients with nonmetastatic castration-resistant prostate cancer and a rising prostate-specific antigen [ClinicalTrials.gov identifier NCT01046916]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 4]
  40. 40.
    Millennium Pharmaceuticals, Inc. Study of TAK-700 in combination with docetaxel and prednisone in men with metastatic castration-resistant prostate cancer [Clinical-Trials.gov identifier NCT01084655]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 4]
  41. 41.
    Tokai Pharmaceuticals. ARMOR1: study of TOK-001 to treat castration resistant prostate cancer [Clinical-Trials.gov identifier NCT00959959]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 4]
  42. 42.
    Aragon Pharmaceuticals, Inc. Safety, pharmacokinetic and proof-of-concept study of ARN-509 in castration-resistant prostate cancer (CRPC) [ClinicalTrials.gov identifier NCT01171898]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 4]
  43. 43.
    AstraZeneca. Open label prostate cancer study [Clinical-Trials.gov identifier NCT01162395]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 4]
  44. 44.
    Enzon Pharmaceuticals, Inc. A phase 1a/1b study to evaluate the safety of EZN-4176, in adult patients with castration-resistant prostate cancer [ClinicalTrials.gov identifier NCT01337518]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 4]
  45. 45.
    Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009 May 8; 324 (5928): 787–90PubMedCrossRefGoogle Scholar
  46. 46.
    Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 2010 Apr 24; 375 (9724): 1437–46PubMedCrossRefGoogle Scholar
  47. 47.
    Medivation, Inc. A safety and efficacy study or oral MDV3100 in chemotherapy-naïve patients with progressive metastatic prostate cancer [ClinicalTrials.gov identifier NCT01212991]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 4]
  48. 48.
    Astellas Pharma Inc. A study to test if MDV3100 is effective and safe prostate cancer patients who have never had hor-mone therapy [ClinicalTrials.gov identifier NCT01302041]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 4]
  49. 49.
    Astellas Pharma Inc. A study of MDV3100 versus bicalutamide in castrate men with metastatic prostate cancer [ClinicalTrials.gov identifier NCT01288911]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 4]
  50. 50.
    Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 Oct 7; 351 (15): 1502–12PubMedCrossRefGoogle Scholar
  51. 51.
    Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 Oct 7; 351 (15): 1513–20PubMedCrossRefGoogle Scholar
  52. 52.
    Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007 Feb 20; 25 (6): 669–74PubMedCrossRefGoogle Scholar
  53. 53.
    Scher HI, Chi KN, De Wit R, et al. Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): results from the phase III ASCENT2 trial [abstract 4509]. J Clin Oncol 2010; 28 (15 Suppl.)Google Scholar
  54. 54.
    Sanofi-Aventis. Cabazitaxel at 20 mg/m2 compared to 25 mg/m2 with prednisone for the treatment of metastatic castration resistant prostate cancer (PROSELICA) [ClinicalTrials.-gov identifier: NCT01308580]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 16]
  55. 55.
    Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000 Dec 1; 18 (23): 3894–903PubMedGoogle Scholar
  56. 56.
    Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006 Jul 1; 24 (19): 3089–94PubMedCrossRefGoogle Scholar
  57. 57.
    Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009 Aug 15; 115 (16): 3670–9PubMedCrossRefGoogle Scholar
  58. 58.
    Nabhan C, Gomella LG, DeVries T, et al. An analysis to quantify the overall survival (OS) benefit of sipuleucel-T accounting for the crossover in the control arm of the IMPACT study [abstract no. 144]. J Clin Oncol 2012; 30 Suppl. 5Google Scholar
  59. 59.
    Longo DL. New therapies for castration-resistant prostate cancer. N Engl J Med 2010 Jul 29; 363 (5): 479–81PubMedCrossRefGoogle Scholar
  60. 60.
    Figg WD, Hussain MH, Gulley JL, et al. A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J Urol 2009 Mar; 181 (3): 1104–13; discussion 13PubMedCrossRefGoogle Scholar
  61. 61.
    Small EJ, Demkow T, Gerritsen WR, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). ASCO Genitourinary Cancers Symposium; 2009 Feb 26–28; Orlando (FL)Google Scholar
  62. 62.
    Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in me-tastatic castration-resistant prostate cancer. J Clin Oncol 2010 Mar 1; 28 (7): 1099–105PubMedCrossRefGoogle Scholar
  63. 63.
    BN ImmunoTherapeutics. A phase 3 efficacy study of a recombinant vaccinia virus vaccine to treat metastatic prostate cancer (Prospect). [ClinicalTrials.gov identifier: NCT01322490]. US National Institutes of Health, Clin-icalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 16]
  64. 64.
    McNeel DG, Dunphy EJ, Davies JG, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 2009 Sep 1; 27 (25): 4047–54PubMedCrossRefGoogle Scholar
  65. 65.
    Nanus DM, Milowsky MI, Kostakoglu L, et al. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 2003; 170 (6 Pt 2): S84–8PubMedCrossRefGoogle Scholar
  66. 66.
    Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 1771 utetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005 Jul 20; 23 (21): 4591–601PubMedCrossRefGoogle Scholar
  67. 67.
    Galsky MD, Eisenberger M, Moore-Cooper S, et al. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol 2008 May 1; 26 (13): 2147–54PubMedCrossRefGoogle Scholar
  68. 68.
    Progenics Pharmaceuticals, Inc. Prostate-specific membrane antigen antibody-drug conjugate in subjects with prostate cancer [ClinicalTrials.gov identifier: NCT01414283]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 16]
  69. 69.
    Slovin SF BT, Higano CS. Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC) [abstract no. 5138]. J Clin Oncol 2009; 27 (15 Suppl.)Google Scholar
  70. 70.
    Bristol-Myers Squibb. Study of immunotherapy to treat advanced prostate cancer [ClinicalTrials.gov identifier: NCT00861614]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 16]
  71. 71.
    Bristol-Myers Squibb. Phase 3 study of immunotherapy to treat advanced prostate cancer [ClinicalTrials.gov identifier: NCT01057810]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 17]
  72. 72.
    Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmaco-dynamics, and immunologic correlates. J Clin Oncol 2010 Jul 1; 28 (19): 3167–75PubMedCrossRefGoogle Scholar
  73. 73.
    Fox WD, Higgins B, Maiese KM, et al. Antibody to vascular endothelial growth factor slows growth of an an-drogen-independent xenograft model of prostate cancer. Clin Cancer Res 2002 Oct; 8 (10): 3226–31PubMedGoogle Scholar
  74. 74.
    Kelly WK, Halabi S, Carducci MA, et al. A randomized, double-blind, placebo-controlled phase III trial comparing doectaxel, prednisone and placebo with docetaxel, prednisone and bevacizumab in men with metastatic castration-reesitant prostate cancer (mCRPC): survival results of CALGB 90401 [abstract no. LBA4511]. J Clin Oncol 2010; 28 (7s)Google Scholar
  75. 75.
    Sanofi-Aventis. Aflibercept in combination with docetaxel in metastatic androgen independent prostate cancer (VENICE) [ClinicalTrials.gov identifier: NCT00519285]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 17]
  76. 76.
    Ning YM, Gulley JL, Arlen PM, et al. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010 Apr 20; 28 (12): 2070–6PubMedCrossRefGoogle Scholar
  77. 77.
    Celgene Corporation. Study to evaluate safety and effectiveness of lenalidomide in combination with docetaxel and prednisone for patients with castrate-resistant prostate cancer (Mainsail) [ClinicalTrials.gov identifier: NCT00988208]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 17]
  78. 78.
    Celgene. Celgene will discontinue phase III MAINSAIL(R) trial in castrate-resistant prostate cancer [media release]. 2011 [online]. Available from URL: http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1633148&highlight= [Accessed 2012 Mar 21]
  79. 79.
    Pili R, Haggman M, Stadler WM, et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 2011; 29 (30): 4022–8PubMedCrossRefGoogle Scholar
  80. 80.
    Active Biotech AB. A study of tasquinimod in men with metastatic castrate resistant prostate cancer [Clinical-Trials.gov identifier: NCT01234311]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 17]
  81. 81.
    Pfizer. Sunitinib plus prednisone in patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy (SUN 1120) [ClinicalTrials.gov identifier: NCT00676650]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 17]
  82. 82.
    Aragon-Ching JB, Jain L, Gulley JL, et al. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 2009 Jun; 103 (12): 1636–40PubMedCrossRefGoogle Scholar
  83. 83.
    Hussain MRS, Sweeney C, Corn PG, et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial [abstract no. 4516]. J Clin Oncol 2011; 29 Suppl.Google Scholar
  84. 84.
    Lockhart AC, Rothenberg ML, Dupont J, et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 2010 Jan 10; 28 (2): 207–14PubMedCrossRefGoogle Scholar
  85. 85.
    Isambert N, Freyer G, Zanetta S et al. A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGFtrap) plus docetaxel (D) in patients (pts) with advanced solid tumors:preliminary results. J Clin Oncol 2008; 28 Suppl. 18sGoogle Scholar
  86. 86.
    Sonpavde G, Periman PO, Bernold D, et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010 Feb; 21 (2): 319–24PubMedCrossRefGoogle Scholar
  87. 87.
    Dror Michaelson M, Regan MM, Oh WK, et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009 May; 20 (5): 913–20PubMedCrossRefGoogle Scholar
  88. 88.
    Michaelson MD, Oudard S, Ou Y, et al. Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC) [abstract no. 4515]. J Clin Oncol 2011; 29 Suppl.Google Scholar
  89. 89.
    Exelixis. Exelixis’ cabozantinib meets primary endpoint in phase 3 clinical trial for medullary thyroid cancer [media release]. 2011 Oct 24 [online]. Available from URL: http://www.exelixis.com/investors-media/press-releases [Accessed 2012 Mar 17]
  90. 90.
    Chen M, Pratt CP, Zeeman ME, et al. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell 2011 Aug 16; 20 (2): 173–86PubMedCrossRefGoogle Scholar
  91. 91.
    Higano C, Alumkal J, Ryan CJ et al. A phase II study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody (Mab) against the insulin-like growth factor-1 receptor (IGF-1R), as monotherapy in patients with metastatic, asymptomatic castration-resistant prostate cancer (CRPC) [abstract no. 5142]. J Clin Oncol 2009; 27 (15 Suppl.)Google Scholar
  92. 92.
    Pfizer. Study of CP-751,871 in combination with docetaxel and prednisone in patients with hormone insensitive prostate cancer (HRPC) [ClinicalTrials.gov identifier: NCT00313781]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 17]
  93. 93.
    Yu EY, Wilding G, Posadas E, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009 Dec 1; 15 (23): 7421–8PubMedCrossRefGoogle Scholar
  94. 94.
    Yu EY, Massard C, Gross ME, et al. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology 2011 May; 77 (5): 1166–71PubMedCrossRefGoogle Scholar
  95. 95.
    Araujo J, Armstrong AJ, Braud EL, et al. Dasatinib and docetaxel combination treatment for patients with cas-tration-resistant progressive prostate cancer: a phase I/II study (CA180086) [abstract no. 5061]. J Clin Oncol 2009; 27 (15 Suppl.)Google Scholar
  96. 96.
    Bristol-Myers Squibb. Randomized study comparing docetaxel plus dasatinib to docetaxel plus placebo in castration-resistant prostate cancer (READY) [ClinicalTrials.gov identifier: NCT00744497]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 17]
  97. 97.
    Chi KN, Hotte SJ, Yu EY, et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010 Sep 20; 28 (27): 4247–54PubMedCrossRefGoogle Scholar
  98. 98.
    Morgan TM, Koreckij TD, Corey E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 2009 Mar; 9 (2): 237–49PubMedCrossRefGoogle Scholar
  99. 99.
    Gray IC, Stewart LM, Phillips SM, et al. Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer 1998 Nov; 78 (10): 1296–300PubMedCrossRefGoogle Scholar
  100. 100.
    Hodgson MC, Shao LJ, Frolov A, et al. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res 2011 Jan 15; 71 (2): 572–82PubMedCrossRefGoogle Scholar
  101. 101.
    Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366 (6): 520–9PubMedCrossRefGoogle Scholar
  102. 102.
    Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011 May 17; 19 (5): 575–86PubMedCrossRefGoogle Scholar
  103. 103.
    de Bono JS, Bellmunt J, Attard G, et al. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol 2007 Jan 20; 25 (3): 257–62PubMedCrossRefGoogle Scholar
  104. 104.
    Fizazi K. The role of Src in prostate cancer. Ann Oncol 2007 Nov; 18 (11): 1765–73PubMedCrossRefGoogle Scholar
  105. 105.
    Sanjay A, Houghton A, Neff L, et al. Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast motility. J Cell Biol 2001 Jan 8; 152 (1): 181–95PubMedCrossRefGoogle Scholar
  106. 106.
    Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 2009 Jan 1; 15 (1): 9–14PubMedCrossRefGoogle Scholar
  107. 107.
    Saporita AJ, Ai J, Wang Z. The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate 2007 Apr 1; 67 (5): 509–20PubMedCrossRefGoogle Scholar
  108. 108.
    Heath EI, Hillman DW, Vaishampayan U, et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2008 Dec 1; 14 (23): 7940–6PubMedCrossRefGoogle Scholar
  109. 109.
    Miyake H, Chi KN, Gleave ME. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2000 May; 6 (5): 1655–63PubMedGoogle Scholar
  110. 110.
    Teva Pharmaceutical Industries. Comparison of docetaxel/prednisone to docetaxel/prednisone in combination with OGX-011 in men with prostate cancer (SYNERGY) [ClinicalTrials.gov identifier: NCT01188187]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 17]
  111. 111.
    OncoGenex Technologies. A study evaluating the pain palliation benefit of adding custirsen to docetaxel re-treatment of cabazitaxel as second line therapy in men with metastatic castrate resistant prostate cancer (mCRPC) [ClinicalTrials.gov identifier: NCT01083615]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 17]
  112. 112.
    Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004 Jun 2; 96 (11): 879–82PubMedCrossRefGoogle Scholar
  113. 113.
    Fizazi K, Beuzeboc P, Lumbroso J, et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2009 May 20; 27 (15): 2429–35PubMedCrossRefGoogle Scholar
  114. 114.
    Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001 Feb 3; 357 (9253): 336–41PubMedCrossRefGoogle Scholar
  115. 115.
    Murphy WM, Soloway MS, Barrows GH. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 1991 Aug 15; 68 (4): 821–8PubMedCrossRefGoogle Scholar
  116. 116.
    Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011 Mar 5; 377 (9768): 813–22PubMedCrossRefGoogle Scholar
  117. 117.
    AMGEN. Phase 3 data demonstrate XGEVA(TM) (Denosumab) is first bone targeted therapy to prevent spread of cancer to the bone in men with advanced prostate cancer [media release]. 2011 Aug 21 [online]. Available from URL: http://wwwext.amgen.com/media/media_pr_detail.jsp?year=2011&releaseID=1564774 [Accessed 2012 Mar 17]

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Deborah Mukherji
    • 1
  • Andrew Eichholz
    • 1
  • Johann S. De Bono
    • 1
  1. 1.Institute of Cancer ResearchSutton SurreyUK

Personalised recommendations